A call to cellular and humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A

Human Vaccines

Volumn 4, Issue 2, 2008, Pages 148-157

  McMurry, Julie A ^a   Johansson, Bert E ^a   De Groot, Anne S ^a,b  

^a EpiVax Inc   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

B cell; Cognate; Epitope; Help; Influenza; T cell

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; M2E PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANTIBODY RESPONSE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CORRELATION ANALYSIS; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG EFFICACY; EVOLUTIONARY ADAPTATION; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; NOTE; POINT MUTATION; SINGLE DRUG DOSE; T LYMPHOCYTE; TH1 CELL; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 45849127634     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.2.5169     Document Type: Note

References (132)

1. Osterholm MT. Preparing for the next pandemic. N EngI J Med 2005; 352:1839-42.
2. Anders EM, Peppard PM, Burns WH, White DO. In vitro antibody response to influenza virus. T cell dependence of secondary response to hemagglutinin. J Immunol 1979; 123:1356-61.
3. Johansson BE, Moran TM, Bona CA, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin: Reduced generation of neuramindase specific Helper T cells in hemagglutinin primed mice. J Immunol 1987; 139:2015-9.
4. Johansen P, Stamou P, Tascon RE, Lowrie DB, Stockinger B. CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur J Immunol 2004; 34:91-7.
5. Kilbourne ED. What are the prospects for a universal influenza vaccine? Nat Med 1999; 5:1119-20.
6. Choppin P, and Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. Reactivity with virus inhibitors in normal sera. J Exp Med 1960; 112:921.
7. Johansson B, Bucher D, and Kilbourne E. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virology 1989; 63:1239.
8. Compans R, Klenk H-D, Caliguiri L, Choppin P. Influenza virus proteins. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology 1970; 42:880.
9. Kilbourne ED. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis, 1976; 134: 385.
10. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 1982; 36:1102-8.
11. Burlington DB, Clements ML, Meiklejohn G, Phelan M, Murphy BR. Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect Immun 1983; 41: 540-5
12. Paul WE and Benacerraf B. Functional specificity of thymus-dependent lymphocytes. Science 1977; 195:1293
13. Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 1986; 164:1114-28.
14. Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 1979; 280:147-8.
15. LaMontagne JR, Noble GR, Quinnan GV, Curlin GT, Blackwelder WC, Smith JI, Ennis FA, Bozeman FM. Summary of clinical trials of inactivated influenza vaccine 1978. Rev Infect Dis 1983; 5:723-36.
16. Liu W, Li H, Chen Y-H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003; 35:141-6.
17. Flynn KJ, Belz GT, Airman JD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998; 8:683-91.
18. Johansson BE, Bucher DJ, Pokorny BA and Kilbourne ED. Identification of PR-8 Ml protein influenza high-yield reassortants by Ml-specific monoclonal antibodies. Virology 1989; 171:634-6.
19. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol 2006; 7:449-55.
20. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, C. Hay M, Wolff M, She D, Cox MJM. Dose-Related Safety and Immunogenicity of a Trivalent Baculovirus-Expressed Influenza-Virus. J Inf Dis 2006; 193:1223.
21. Powers D, Smith G, Anderson E, Kennedy D, Hackett C, Wilkinson B, et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996; 173:1467-70.
22. Kilbourne ED, Johansson BE, Moran TM, Wu S, Pokorny BA, Xu X, and Cox N. Implications for vaccine production of influenza A virus hemagglutinin polymorphism. Pleotropic antigenic variant of A/Shangai/11/87 (H3N2) virus selected as high-yield reassortant. J Gen Virol 1993; 74:1311-6.
23. Huddleston JA, Brownlee GG. The sequence of the nucleoprotein gene of human influenza A virus, strain A/NT/60/68. Nucleic Acids Res 1982; 10:1029-38.
24. Berton MT, Naeve CW, Webster RG. Antigenic structure of the influenza B virus hemagglutinin: nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies. J Virol 1984; 52: 919-27.
25. Air GM, Laver WG, Webster RG. Antigenic variation in influenza viruses. Contrib Microbiol Immunol 1987; 8:20-59. Review.
26. Cruse JM, Lewis RB. Contemporary concepts of antigenic variation. Contra Micro Immuno 1987; 8:1-19.
27. Campbell CH, Webster RG, and Breese SS Jr. The in vivo production of "new" influenza A viruses. Virology 1971; 44:317-28.
28. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-93.
29. Henry M, Kieny M, Thompson, R. Immediate and sustained action required to sharply increase pandemic influenza vaccine supply. WHO mediacentre. Last updated 23 October 2006. Retrieved 15 November, 2006 from http://www.who.int/ mediacentre/news/releas-es/2006/pr58/en/index.html.
30. Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339:273-80.
31. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59:1-15.
32. Glezen WP. Cold-adapted, live attenuated influenza vaccine. Expert Rev Vaccines 2004; 3:131-9.
33. Gross P, Ennis F, Gaerlan L, Denson L, Denning C, Schiffman D. A controlled double-blind comparison of the reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Inf Dis 1977; 136:623.
34. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3: CD004876.
35. Besselaar TG, Botha L, McAnerney JM, Schoub BD. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J Med Virol 2004; 73:71-8.
36. McLaren C, Verbonitz MW, Daniel S, Guggs G, Ennis E Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J Immuno 1977; 125:2679
37. Wise T, Polin R, Mazur M, Ennis F. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J Inf Dis 1977; 136:5496.
38. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. PNAS USA 1987; 84:6869-73.
39. Rasmussen IB, Lunde E, Michaelsen TE, Bogen B, Sandlie I. The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination. Proc Natl Acad Sci USA 2001; 98:10296-301.
40. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985; 314: 537.
41. Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am J Respir Crit Care Med 1995; 152:S72-5.
42. McMicheal A, Grotch F, Cullen P, Askonas B, and Webster R. The human cytotoxic T cell response to influenza vaccination. Clin Exp Immunol 1981; 43:276.
43. McLaren C, Verbonitz MW, Daniel S, Guggs G, Ennis F. Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J Immuno 1977; 125:2679
44. Belshe R, Gruber W, Mendelman P, Cho I, Reisinger K, Block S, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatrics 2000; 136:168-175.
45. Kilbourne E. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in the induction of anti-neuraminidase antibody in man. J Inf Dis 1976; 134:384.
46. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96
47. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer j, Batraglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732-7.
48. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wilrse J, Liang H, Gilbert A, Cox M. Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza Vaccine A Randomized Controlled Trial. JAMA 2007; 297:1577-82.
49. Epstein SL. Control of influenza virus infection by immunity to conserved viral features. Expert Rev And Infect Ther 2003; 1:627-38.
50. Cassetti MC, Couch R, Wood J, Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 2005; 23:1529-33.
51. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
52. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
53. Poland GA. Vaccines against avian influenza-a race against time. N Engl J Med 2006; 354:1411-3.
54. Wood JM. Developing vaccines againsr pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001; 356:1953-60.
55. Hehme N, Engelmann H, Künzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002; 191:203-8.
56. Johansson BE, Brett IC, Focosi D, Poland GA. An Inactivated Subvirion Influenza A (H5N1) Vaccine. NEJM 2006; 354:2724-5.
57. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody tesponse to M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993; 74:143-6.
58. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr, Gerhard W. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21:2616-26.
59. Dong L, Mori I, Hossain MJ, Kimura Y. The senescence-accelerated mouse shows aging-related defects in cellular but not humoral immunity against influenza virus infection, J Infect Dis 2000; 182:391-6.
60. Boon AC, de Mutsert G, van Baarle D, et al. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 2004; 172:2453-60.
61. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osrerhaus AD, Rimmelzwaan GF. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612-20.
62. Kamperschroer C, Dibble JP, Meents DL, Schwartzberg PL, Swain SL. SAP is required for Th cell function and for immunity to influenza. J Immunol 2006; 177:5317-27.
63. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherry PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell deficient mice. J Virol 2002; 76:12388-93.
64. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996; 184:863-71.
65. Brooks JW, Hamilton-Easton AM, Christensen JP, Cardin RD, Hardy CL, Doherty PC. Requirement for CD40 ligand, CD4(+) T cells, and B cells in an infectious mononucleosis-like syndrome. J Virol 1999; 73:9650-4.
66. Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002; 20:1670-4.
67. Kendal AP, Bozeman FM, Ennis FA. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 1980; 29:966-71.
68. Nestorowicz A, Laver G, Jackson DC. Antigenic determinants of influenza virus haemagglu-tinin. X. A comparison of the physical and antigenic properties of monomeric and trimeric forms. J Gen Virol 1985; 66:1687-95.
69. Muller, GM., Shapira, M and Arnon, R. Anti-Influenza Response Achieved by Immunization with a synthetic conjugate. PNAS 1982; 79:569-73
70. Nestorowicz A, Tregear GW, Southwell CN, Martyn J, Murray JM, White DO, Jackson DC. Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites. Mol Immunol 1985; 22:145-54.
71. Green N, Alexander H, Olson A, Alexander S, Shinnick TM, Sutcliffe JG, Lerner RA. Immunogenic structure of the influenza virus hemagglutinin. Cell 1982; 28:477-87.
72. Russ G, Styk B, Polakova K. Antigenic glycopeptides HA1 and HA2 of influenza virus hemagglutinin. II. Reactivity with rabbit sera against intact virus and purified undissociated hemagglutinin. Acta Virol 1978; 22:371-82.
73. Graves PN, Schulman JL, Young JF, Palese P. Preparation of influenza virus subviral particles lacking the FIA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983; 126:106-16
74. Varghese JN, Laver, WG and Colman PM. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303:35-40.
75. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sires in influenza virus neuraminidase. Nature 1983; 303:41-44.
76. Biddison WE, Doherry PC, Webster RG. Antibody to influenza virus matrix protein detects a common antigen on the surface of cells infected with type A influenza viruses. J Exp Med 1977; 146:690-7.
77. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res 1986; 3:251-61.
78. Kilbourne ED, Palese P, Schulman JL. Inhibition of viral neuraminidase as a new approach to the prevention of influenza. In Perspectives in virology Vol 9 (Ed. Pollard, M.) New York, Academic Press, 1975; 99-113
79. van Wyke KL, Hinshaw VS, Bean WJ Jr, Webster RG. Antigenic variation of influenza A virus nucleoprotein detected with monoclonal antibodies. J Virol 1980; 35:24-30.
80. Johansson BE, Kilbourne ED. Dissociation of influenza virus neuraminidase from matrix and nulceoprotein eliminates cognate help and antigenic competition. Virology 1996; 225:136-44.
81. Lawson C, Bennink J, Restifo N, Yewdell J, Murphy BR. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. 1994; J Virol 68:3505.
82. Caro-Aguilar I, Rodríguez A, Calvo-Calle JM, Guzmán F, De la Vega P, Pararroyo ME, Galinski MR, Moreno A. Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens Infect Immun 2002; 70: 3479-92.
83. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:15-22.
84. Braciale TJ. Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell Immunol 1977; 33:423-36.
85. Andrew ME, Coupar BE, Ada GL, Boyle DB. Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microb Pathog 1986; 1:443-52.
86. Braciale TJ, Andrew ME, Braciale VL. Heterogeneity and specificity of cloned lines of influenza-virus specific cytotoxic T lymphocytes. J Exp Med 1981; 153:910-23
87. Townsend, ARM, Rothbard J. Gotch FM, Bahadur G, Wraith D, and McMichal AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959-68.
88. Riberdy JM, Christensen JP, Branum K, Doherty PC. Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol 2000; 74:9762-5.
89. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001; 7:1306-12.
90. Marshall DR, Turner SJ, Belz GT, Wingo S, Andreansky S, Sangster MY, et al. Measuring the diaspora for virus-specific CD8+ T cells. PNAS USA 2001; 98:6313-8.
91. McMicheal A, Grotch F, Cullen P, Askonas B, and Webster R. The human cytotoxic T cell response to influenza vaccination. Clin Exp Immunol 1981; 43:276.
92. Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, Bonnefoy JY, Corvaia N. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 2003; 309:320-9.
93. Powell TJ, Brown DM, Hollenbaugh JA, Charbonneau T, Kemp RA, Swain SL, Dutton RW CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency. Clin Immunol 2004; 113:89-100.
94. Neuman G, KawaokaY. Host range restriction and pathogenicity in the context of influenza pandemic. Emerging Infectious Diseases 2006; 12: 881-6.
95. Walter E A, Greenberg PD, Gilberr MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
96. Gelder CM, Welsh KI, Faith A, Lamb JR, Askonas BA. Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection. J Virol 1995; 69:7497-506.
97. Hackett CJ, Hurwitz JL, Dietzschold B, Gerhard W A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus. J Immunol 1985; 135:1391-4.
98. Lamb JR, Eckels DD, Phelan M, Lake P, Woody JN. Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J Immunol 1982; 128:1428-32
99. Hurwitz JL, Hackett CJ, McAndrew EC, Gerhard W Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins. J Immunol 1985; 134:1994-8.
100. Katz JM, Laver WG, White DO, and Anders, EM. Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains. J Immunol 1985; 134:616-22.
101. Hurwitz JL, Herber-Katz E, Hackett CJ, Gerhard W. Characterization of the murine TH response to influenza virus hemagglurinin: evidence for three major specificities. J Immunol 1984; 133:3371-7.
102. Scherle PA, Gerhard W. Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. PNAS USA 1988; 85:4446-50.
103. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. PNAS USA 1987; 84:6869-73.
104. Virelizier JL, Postlethwaite R, Schild GC, Allison AC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. Thymus dependence of antibody formation and thymus independence of immunological memory. J Exp Med 1974; 140:1559-70.
105. Schneider C, Van Regenmortel MH. Immunogenicity of free synthetic peptides corresponding to T helper epitopes of the influenza HA 1 subunit. Induction of virus cross reacting CD4+ T lymphocytes in mice. Arch Virol 1992; 125:103-19.
106. Novak EJ, Liu AW, Nepom GT, Kwok WW. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 1999; 104:R63-7.
107. Danke NA, Kwok WW HLA class II-restricted CD4+ T cell responses directed against influenzaviral antigens postinfluenza vaccination. J Immunol 2003; 171:3163-9.
108. Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, Bunce M, Welsh KI, Marshall SE, Oxford J. Associations between human leukocyte antigens and nonresponsive-ness to influenza vaccine. J Infect Dis 2002; 185:114-7.
109. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and rhe challenge for immunology. Nat Immunol 2006; 7:449-55. Review.
110. Quilligan JJ, Francis T. Serological Response to Intranasal Administration of Inactive Influenza Virus in Children. J Clin Invest 1947; 26:1079-87.
111. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006; 193:49-53.
112. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Cross-subtype protection in humans during sequential overlapping and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis 1985; 151:81-8.
113. Marshall D, Sealy R, Sangster M, Coleclough C. TH Cells Primed During Influenza Virus Infection Provide Help for Qualitatively Distinct Antibody Responses to Subsequent Immunizationl The Journal of Immunology 1999; 163:4673-4682.
114. Seo SH, Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001; 75:2516-25.
115. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000; 81:2689-96
116. Anders EM, Katz JM, Jackson DC, White DO. In vitro antibody response to influenza virus. Specificity of helper T cell recognizing hemagglutinin. J Immunol 1981; 127:669-72.
117. Crowe SR, Miller SC, Brown DM, Adams PS, Dutton RW, Harmsen AG, Lund FE, Randall TD, Swain SL, Woodland DL. Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 2006; 24:457-67.
118. De Groot AS, Jesdale BM, Szu E, Schafer JR. An interactive web site providing MHC ligand predictions: application to HIV research. AIDS Res and Hum Retroviruses 1997; 13:539-41.
119. Schafer JA, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a Matrix-based Algorithm, EpiMatrix. Vaccine 1998; 16:1880-4.
120. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale B, Gonzalez M, Martin W, Saint-Aubin C. From genome to vaccine: In silico predictions, ex vivo verification. Vaccine 2001; 19:4385-95.
121. De Groot AS, Sbai H, Jesdale B, Martin W, Saint Aubin C, Bosma A, Lieberman J, Skowron GA, Mansourati F, Mayer K. Mapping Cross-clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach. Vaccine 2003; 21:4486-504.
122. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73.
123. De Groot AS, Bishop E, Khan B, Lally M, Marcon L, Franco J, Mayer K, Carpenter C, Martin W. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods 2004; 34:476-87.
124. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, Martin W. HIV vaccine development by computer assisted design: the GALA vaccine. Vaccine 2005; 23:2136-48.
125. Fox JP, Hall CE. Viruses in families. Littleton, MA: PSG Publishing Company, 1980.
126. Frank AL, Taber LH, Glezen WP, Paredes A, Couch RB. Reinfection with influenza A (H3N2) virus in young children and their families. J Inf Disease 1979; 140: 829-36.
127. Levi R, Arnon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 1996; 14:85-92.
128. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002; 20:2772-80.
129. Mack J, Falk K, Rotzschke O, Walk T, Strominger JL, Jung G. Synthesis of linear and comb-like peptide constructs containing up to four copies of a T cell epitope and their capacity to stimulate T cells. J Pept Sci 2001; 7:338-45.
130. Santra S, Barouch DH, Kuroda MJ, Schmitz JE, Krivulka GR, Beaudry K, Lord CI, Lifton MA, Wyarr LS, Moss B, Hirsch VM, Lervin NL. Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection. J Virol 2002; 76:6376-81.
131. Subbramanian RA, Kuroda MJ, Charini WA, Barouch DH, Costantino C, Santra S, Schmitz JE, Martin KL, Lifton MA, Gorgone DA, Shiver JW, Letvin NL. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol 2003; 77:10113-8.
132. Rivera DS, McMurry JA, Buus S, Martin W, De Groot AS. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 2007; In Press.